Esteve Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Esteve Sa (US): 4 reconciled FDA prescription therapies (9.4% 2025 to 2030 cliff risk), $6.8M 2024 CMS Part D & Medicaid spend, and 25 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure9.4%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$6.8M
2024 Medicare Part D Spend$4.7M
2024 Medicaid Spend$2.1M
California HCAI SB 17 Filings25 WAC filings (max 203.6% 2-yr change)